NEXT GENERATION RNAI Trademark

Trademark Overview

On Monday, October 7, 2024, a trademark application was filed for NEXT GENERATION RNAI with the United States Patent and Trademark Office. The USPTO has given the NEXT GENERATION RNAI trademark a serial number of 98789219. The federal status of this trademark filing is NEW APPLICATION - ASSIGNED TO EXAMINER as of Thursday, April 10, 2025. This trademark is owned by City Therapeutics, Inc.. The NEXT GENERATION RNAI trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical preparations, including nucleic acid therapeutics for use in the treatment of diseases and disorders, including genetic, neurologic, gastrointestinal, metabolic, immunological, cardiovascular, ocular, and oncological and diseases of the retina, liver, heart, lung, bone marrow, brain, muscle, immune system and kidneys; Pharmaceuticals, biosimilars and biological preparations for medical and therapeutic purposes for use in the treatment of diseases and disorders, including genetic, neurologic, gastrointestinal, metabolic, immunological, cardiovascular, ocular, and oncological and diseases of the retina, liver, heart, lung, bone marrow, brain, muscle, immune system and kidneys

Scientific research; Scientific research in the fields of pharmaceuticals and medicine; Providing scientific information in the field of pharmaceuticals and medicine; Product development for others in the field of pharmaceuticals and medicine
next generation rnai

General Information

Serial Number98789219
Word MarkNEXT GENERATION RNAI
Filing DateMonday, October 7, 2024
Status638 - NEW APPLICATION - ASSIGNED TO EXAMINER
Status DateThursday, April 10, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical preparations, including nucleic acid therapeutics for use in the treatment of diseases and disorders, including genetic, neurologic, gastrointestinal, metabolic, immunological, cardiovascular, ocular, and oncological and diseases of the retina, liver, heart, lung, bone marrow, brain, muscle, immune system and kidneys; Pharmaceuticals, biosimilars and biological preparations for medical and therapeutic purposes for use in the treatment of diseases and disorders, including genetic, neurologic, gastrointestinal, metabolic, immunological, cardiovascular, ocular, and oncological and diseases of the retina, liver, heart, lung, bone marrow, brain, muscle, immune system and kidneys
Goods and ServicesScientific research; Scientific research in the fields of pharmaceuticals and medicine; Providing scientific information in the field of pharmaceuticals and medicine; Product development for others in the field of pharmaceuticals and medicine

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, October 7, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, October 7, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCity Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02141

Trademark Events

Event DateEvent Description
Monday, October 7, 2024NEW APPLICATION ENTERED
Wednesday, April 9, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, April 10, 2025ASSIGNED TO EXAMINER

Related Keywords

rnai generation next pharmaceuticals diseases medicine scientific including marrow brain lung liver muscle